Calliditas Therapeutics IPO Presentation Deck
Market landscape research
Overview of research coverage
Qualitative interviews:
8 payers covering MCO, PBM, IDN, and FFS for
organizations/plans covering over 225 million
U.S. lives
• 12 Nephrologists representing academic
centers, community hospitals and private
practices that treat a minimum of 10 IgAN
patients per month
Quantitative research/survey: 102 Nephrologists
that, on average, treat 14 IgAN patients per
month
calliditas
IMS Health &
Quintiles are now
IQVIA™
Nephrologist summary: perception of Nefecon
Product profile shown to nephrologists mimicked the
Phase 2b NEFIGAN trial results
The majority of nephrologists indicated they would:
Prescribe Nefecon for their IgAN patients within the
first year of being on the market (68%)
• Prescribe Nefecon as the first agent after, or in
conjunction with, ACES/ARBS
90% of the nephrologists familiar with budesonide had a
neutral or favorable opinion when learning the active
ingredient in Nefecon was budesonide
Assuming no tolerability issues, half of nephrologists
indicated an interest in continuing use of Nefecon past its
initial 9-month course
June 2020
23View entire presentation